EUVIMEDEUVIMED entdecken
Crossref

L26/P-754 Desogestrel versus Gonadotropin Releasing Hormone (GnRH) antagonist for luteinizing hormone (LH) suppression in ovarian stimulation for in vitro fertilization (IVF) protocols

M. Samama, D. Oppenheimer, P. Luiza dos Santos, K. Ann Reimão Miller, A. Montoro Françozo Miranda, C. Vitoria Rocha Risegatto, D. Helena Piovesan Maciel, H. Vitoria Fauth, R. Cassia Camargo de Preto Piscopo, L. Carolina Oliveira Rodrigues, I. Sene Rosa, L. Issas de Oliveira und 3 weitere

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Samama und 14 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does LH suppression with desogestrel result in reproductive outcomes comparable to GnRH antagonist suppression in women undergoing IVF treatment? Summary answer In this multicenter retrospective cohort study, LH suppression with desogestrel achieved reproductive outcomes comparable to GnRH antagonist suppression in IVF cycles. What is known already Preventing a premature LH surge is a key component of controlled ovarian stimulation for IVF. GnRH antagonists are the most commonly used agents for this purpose. In recent years, progestin-based approaches have been explored as an alternative, offering oral administration and a simplified dosing regimen with lower costs. Desogestrel is a progestin with a long half-life and establishes hypothalamic-pituitary suppression with a single oral daily dose. However, data evaluating its use as a method of LH suppression in IVF cycles are currently lacking. Study design, size, duration This multicenter retrospective cross-sectional study included data from 150 participants undergoing LH suppression during ovarian stimulation IVF protocols across five fertility centers envolved in low-cost educational program in Brazil. Eighty-five participants were given desogestrel for this purpose and 65 received GnRH antagonists. Data collection was completed in 2025. Participants/materials, setting, methods Women age at inclusion ranged from 31-45 years. The study compared the use of desogestrel and GnRH antagonists for outcomes associated with the suppressing of LH in ovarian stimulation for IVF protocols. Outcomes included total gonadotropin dose, number of mature oocytes (1–10/>10), and blastocysts (≥5/1–4). Among participants with embryo transfer (N = 87), β-human chorionic gonadotropin hormone (β-hCG) results (positive/negative) and clinical pregnancy (yes/no). Binary logistic regression models were applied. Main results and the role of chance No significant age differences were observed between groups. Participants receiving <1500 IU of gonadotropins were more likely to belong to the desogestrel group than to the GnRH antagonist group compared with those receiving 1500-2500 IU (OR = 3.34; 95%CI=1.22-9.10; p = 0.019). Those with ≥5 blastocyst-stage embryos showed higher odds of having received desogestrel than GnRH antagonists compared with those who produced 1-4 embryos at this stage (OR = 2.86; 95%CI=1.20-6.82; p = 0.017). The number of retrieved oocytes (OR = 0.64; 95%CI=0.32-1.26; p = 0.191) and mature oocytes (OR = 0.70; 95%CI=0.33-1.49; p = 0.355) showed no statistical differences between groups. Considering only cases with confirmed embryo transfer, results followed the same pattern for the aforementioned variables. No significant differences were found between groups for β-hCG results (OR = 2.23; 95%CI=0.91-5.46; p = 0.078) and clinical pregnancy confirmation (OR = 2.18; 95%CI=0.89-5.37; p = 0.090). Still considering only embryo transfer cases, clinical pregnancy was confirmed in 27 of 40 participants (67.5%) in the desogestrel group. In the antagonist group (n = 41), it occurred in 20 participants (48.8%). These findings suggest that desogestrel use provided results comparable to GnRH antagonists across all evaluated outcomes. Limitations, reasons for caution There was a potential variability in data recording across centers. In addition, categorical use of variables limited statistical modeling for covariate adjustment. Wider implications of the findings Preliminary results suggest desogestrel effectively suppresses LH in ovarian stimulation for IVF, yielding outcomes equivalent to GnRH antagonists regarding oocyte number, β-hCG results and clinical pregnancy. Its association with lower gonadotropin doses and greater number of blastocyst-stage embryos may translate into higher cumulative outcome and reduced costs for IVF protocols. Trial registration number Yes

Zitieren

APA

Samama, M., Oppenheimer, D., Santos, P. L. D., Miller, K. A. R., Miranda, A. M. F., Risegatto, C. V. R., Maciel, D. H. P., Fauth, H. V., Piscopo, R. C. C. D. P., Rodrigues, L. C. O., Rosa, I. S., Oliveira, L. I. D., Bella, Z. J. D., Entezami, F., & Ueno, J. (2026). L26/P-754 Desogestrel versus Gonadotropin Releasing Hormone (GnRH) antagonist for luteinizing hormone (LH) suppression in ovarian stimulation for in vitro fertilization (IVF) protocols. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1081

Vancouver

Samama M, Oppenheimer D, Santos PLD, Miller KAR, Miranda AMF, Risegatto CVR, et al. L26/P-754 Desogestrel versus Gonadotropin Releasing Hormone (GnRH) antagonist for luteinizing hormone (LH) suppression in ovarian stimulation for in vitro fertilization (IVF) protocols. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1081

BibTeX
@article{Samama2026,
  author = {Samama, M. and Oppenheimer, D. and Santos, P. Luiza dos and Miller, K. Ann Reimão and Miranda, A. Montoro Françozo and Risegatto, C. Vitoria Rocha and Maciel, D. Helena Piovesan and Fauth, H. Vitoria and Piscopo, R. Cassia Camargo de Preto and Rodrigues, L. Carolina Oliveira and Rosa, I. Sene and Oliveira, L. Issas de and Bella, Z. Jarmy Di and Entezami, F. and Ueno, J.},
  title = {L26/P-754 Desogestrel versus Gonadotropin Releasing Hormone (GnRH) antagonist for luteinizing hormone (LH) suppression in ovarian stimulation for in vitro fertilization (IVF) protocols},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1081}
}
Kostenlos starten →